DEF — Defense
Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
Lobbyists: STEVEN WOLFE
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
210702ee-1574-4f22-961e-1d7fd583d04aQ1 — 1st Quarter - ReportSTRATEGIC MARKETING INNOVATIONS
Federal relations firm
Clinical-stage biopharmaceutical company
DEF — DefensePatient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
Lobbyists: STEVEN WOLFE
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
HCR — Health IssuesPatient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
Lobbyists: STEVEN WOLFE
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page. Want to partner? Contact us.
Estimated value: $540/mo per user — but we made it free.